RLAY Relay Therapeutics
- 6.420
- +0.110+1.74%
- 6.480
- +0.060+0.93%
Relay Therapeutics News
Relay Therapeutics Upgraded by Barclays Ahead of Data Readout
Relay Therapeutics Raised to Overweight From Equal-Weight by Barclays
Relay Therapeutics Raised to Overweight From Equal-Weight by Barclays
Barclays Upgrades Relay Therapeutics to Overweight, Maintains Price Target to $15
Barclays analyst Peter Lawson upgrades Relay Therapeutics (NASDAQ:RLAY) from Equal-Weight to Overweight and maintains the price target from $15 to $15.
Optimistic Buy Rating for Relay Therapeutics: Pipeline Progress and Financial Stability Drive Analyst Confidence
Relay Therapeutics Price Target Maintained With a $24.00/Share by JMP Securities
Relay Therapeutics Price Target Maintained With a $24.00/Share by JMP Securities
Oppenheimer: The Relay Therapeutics (RLAY.US) rating was reaffirmed, and the target price was adjusted from better than market to better than market, and the target price was adjusted from $33.00 to $25.00.
Oppenheimer: The Relay Therapeutics (RLAY.US) rating was reaffirmed, and the target price was adjusted from better than market to better than market, and the target price was adjusted from $33.00 to $25.00.
Oppenheimer Reiterates Outperform on Relay Therapeutics, Lowers Price Target to $25
Oppenheimer analyst Matthew Biegler reiterates Relay Therapeutics (NASDAQ:RLAY) with a Outperform and lowers the price target from $33 to $25.
Relay Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/06/2024 256.63% Oppenheimer $33 → $25 Reiterates Outperform → Outperform 02/22/2024 327.96% Stifel $25
Analysts Are Bullish on These Healthcare Stocks: Relay Therapeutics (RLAY), Kura Oncology (KURA)
We Think Relay Therapeutics (NASDAQ:RLAY) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although software-as-a-service business Salesforce.com lost money for years while it grew rec
Relay Therapeutics First Quarter 2024 Earnings: Beats Expectations
Barclays Keeps Their Hold Rating on Relay Therapeutics (RLAY)
Relay Therapeutics GAAP EPS of -$0.62 Beats by $0.10, Revenue of $10.01M Beats by $9.09M
Relay Therapeutics Outperforms Revenue Expectations in Q1 2024
Relay Therapeutics Q1 2024 GAAP EPS $(0.62) Beats $(0.71) Estimate, Sales $10.007M Beat $87.500K Estimate
Relay Therapeutics (NASDAQ:RLAY) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate of $(0.71) by 12.68 percent. This is a 20.51 percent increase over losses of $
Earnings Flash (RLAY) RELAY THERAPEUTICS Reports Q1 Revenue $10M
04:25 PM EDT, 05/02/2024 (MT Newswires) -- Earnings Flash (RLAY) RELAY THERAPEUTICS Reports Q1 Revenue $10M
Relay Therapeutics 1Q Loss/Shr 62c >RLAY
Relay Therapeutics 1Q Loss/Shr 62c >RLAY
Press Release: Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights
Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights Approximately $750 million in cash, cash equivalents and investments at end of Q1 2024, expected to fund opera
Relay Therapeutics to Announce First Quarter 2024 Financial Results and Corporate Highlights on May 2, 2024
CAMBRIDGE, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational
Relay Therapeutics to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational
Analysis
Price Target
No Data
